Journal of Histochemistry and Cytochemistry, Vol. 49, 1323-1324, October 2001, Copyright © 2001, The Histochemical Society, Inc.


BRIEF REPORT

Towards a Molecular Classification of Hematolymphoid Neoplasms: Where Are We Now? Where Are We Going?

Eric D. Hsia
a Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence to: Eric D. Hsi, Dept. of Clinical Pathology, L-11, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. E-mail: hsie@ccf.org


  Summary
Top
Summary
Introduction
Literature Cited

Beginning with the discovery of the Philadelphia chromosome in 1960, our descriptions and definitions of hematological malignancies have been successively refined and revised to include morphological, immunophenotypic, and molecular genetic features. As hematopathologists, we now see beyond architectural and cytologic alterations and have, to some degree, become molecular morphologists. Indeed, our "view" of diseases now includes a rudimentary understanding of the molecular genetic abnormalities present in the cells we study under the microscope. (J Histochem Cytochem 49:1323–1324, 2001)

Key Words: hematological malignancy, leukemia, lymphoma, molecular hematopathology


  Introduction
Top
Summary
Introduction
Literature Cited

THE UPCOMING World Health Organization (WHO) classification of hematolymphoid malignancy reflects our attempts to define diseases at the molecular level (Harris et al. 1999 ). For example, diseases such as chronic myelogenous leukemia (CML), acute myeloid leukemia (AML) M3 with t(15;17), AML with t(8;21), AML with inv16, and acute lymphoblastic leukemia (ALL) with t(12;21) are defined and even named by their characteristic translocation. Among non-Hodgkin lymphomas, follicular lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Burkitt lymphoma, and ALK+ anaplastic large-cell lymphoma have characteristic genetic abnormalities that help define them (Harris et al. 1999 ). These molecular genetic abnormalities improve diagnostic accuracy, yield clues to the cellular mechanisms of disease, and may even serve as the basis for specific therapies.

Perhaps the two best known examples of this are all-trans retinoic acid (ATRA) for AML-M3 with the t(15;17) and the tyrosine kinase inhibitor STI-571 in CML. The t(15:17) results in the fusion of the zinc finger-containing gene PML and nuclear hormone receptor RAR gene (Melnick and Licht 1999 ). Detection of this translocation helps to confirm the morphological diagnosis. The PML-RAR fusion protein has enhanced interaction with the N-CoR/Sin3/HDAC1 co-repressor apparatus and thus functions as a transcriptional repressor (Melnick and Licht 1999 ). ATRA at pharmacological concentrations overcomes this interaction (Tallman 1998 ). In CML, the presence of the bcr-abl translocation also helps define the disease entity. At the biological level, the translocation constitutively activates the abl tyrosine kinase (Thijsen et al. 1999 ). This leads to malignant transformation through interference in normal cellular processes such as cell growth, adhesion, and cell death. One of the most exciting developments in rational drug design is the tyrosine kinase inhibitor STI-571, which targets this abnormally activated tyrosine kinase. Clinical trials of STI-571 show great promise as a new treatment modality (Kantarjian et al. 2000 ).

Although specific therapies are not as far advanced in the area of mature B-lymphoid malignancies, significant progress is being made in the molecular genetic classification of disease. Two examples include B-cell chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). In CLL, two subtypes have recently been defined based on mutational status of the immunoglobulin heavy chain (IgH) gene. Cases demonstrating somatic mutation, similar to post-germinal center B-cells, have a significantly better survival than those with germline IgH genes (Hamblin et al. 1999 ). This molecular genetic subdivision of CLL is changing our concept of the disease and appears to help us distinguish between clinically and biologically distinct diseases within a morphologically uniform group. Considerable excitement has also been generated by the analysis of DLBCL with high-density expression arrays. It is well known that DLBCL is a biologically heterogeneous disease. This is reflected in the clinical behavior of patients with DLBCL. Attempts are now being made to classify these cases at the molecular genetic level. In a series of well-characterized DLBCLs, two major types of DLBCL were identified by their patterns of gene expression: the activated B-cell-like and the germinal center-like types (Alizadeh et al. 2000 ). The patients with the former type of DLBCL had a significantly worse outcome compared to those with the latter type, even when stratified by standard clinical prognostic parameters.

These examples illustrate our movement into a new era of molecular genetic classification, molecular diagnosis, and rational drug design in hematological malignancy. They may be seen as paradigms for the application of molecular genetic tools to help separate and define distinct diseases. The unique patterns of tumor gene expression (transcriptomes) and protein expression (proteomes) may then serve as the basis for developing targeted therapies for these molecularly defined entities.


  Footnotes

Presented in part at the Joint Meeting of the Histochemical Society and the International Society for Analytical and Molecular Morphology, Santa Fe, NM, February 2–7, 2001.

Received for publication December 26, 2000; accepted February 16, 2001.
  Literature Cited
Top
Summary
Introduction
Literature Cited

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511[Medline]

Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854[Abstract/Free Full Text]

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller–Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, VA, November 1997. J Clin Oncol 17:3835-3849[Abstract/Free Full Text]

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Resta D, Capdeville R, Druker B (2000) Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia. Blood 96:470a

Melnick A, Licht JD (1999) Deconstructing a disease: RAR, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215[Free Full Text]

Tallman MS (1998) Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Leukemia 12(suppl 1):S37-40[Medline]

Thijsen S, Schuurhuis G, van Oostveen J, Ossenkoppele G (1999) Chronic myeloid leukemia from basics to bedside. Leukemia 13:1646-1674[Medline]





This Article
Abstract
Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Google Scholar
Articles by Hsi, E. D.
Articles citing this Article
PubMed
PubMed Citation
Articles by Hsi, E. D.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]